A recent study by Transparency Market Research (TMR) forecasts that the global hospital infection therapeutics market will grow at a CAGR of 3.1% between 2014 and 2020. TMR, a market intelligence company based in the United States, in its recently released report states, that the global hospital infection therapeutics market is anticipated to reach a market value worth US$3.62 billion by 2020 from US$3.06 billion in 2013. The report titled “Hospital Infection Therapeutics Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020” is available for sale on the website.
Browse the full Hospital Infection Therapeutics Market Report at http://www.transparencymarketresearch.com/hospital-infection-therapeutics.html
According to this market research report, a growing geriatric population, rising demand for better therapeutic drugs, high incidence of hospital infections, and greater healthcare awareness are a few of the prominent factors that drive the global hospital infection therapeutics market. The infections which the patients undergoing treatments in hospitals contract during their stay in the hospitals are known as hospital-acquired infections (HAI) or hospital infections. These infections spread in healthcare settings such as nursing homes, rehabilitation centers, hospitals, dialysis centers, and outpatient surgery centers. It has been observed that most cases of hospital infections originate from the ICUs (Intensive Care Units) as against other divisions.
The TMR report segments the global hospital infection therapeutics market on the basis of drug type, major infections, and geography. On the basis of drug type, this market is segmented into antifungal drugs, antibacterial drugs, and antiviral drugs. Based on major infections, the hospital infection therapeutics market is segmented into bloodstream infections, gastrointestinal disorders, hospital-acquired pneumonia...